Moderate riskFDA DrugClass II

Baxter Clindamycin Phosphate injection recalled for manufacturing compliance deviations

Baxter Healthcare Corporation is recalling a specific lot of Clindamycin Phosphate in 0.9% Sodium Chloride Injection due to deviations from current Good Manufacturing Practice (CGMP) standards during production. The affected lot (NC193689, expiring 10/16/2027) was distributed nationwide, as well as to Puerto Rico and Chile.

From the FDA notice · Read the official notice ↗ · All Baxter recalls

What to do

  1. If you have this medication, contact your pharmacy or healthcare provider immediately with the lot number.
  2. Do not use this lot. Return it to your pharmacy or follow your healthcare provider's instructions for safe disposal.
  3. Ask your healthcare provider about alternative treatment options if you need this medication.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), 50 mL Single-Dose GALAXY Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-9549-50.
Sold in
Nationwide
Made for
Adults

This recall covers 17 products — see all of them.

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
1 Baxter Pkwy, N/A, Deerfield, IL, United States
Classification
Class II
Recall number
D-0816-2026

In the FDA's words

Description
Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), 50 mL Single-Dose GALAXY Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-9549-50. CGMP Deviations Lot # NC193689, Exp Date: 10/16/2027. Distribution: US Nationwide; Puerto Rico; and Chile. Affected quantity: N/A
Hazard
CGMP Deviations

17 products in this recall

Baxter IV drug bags recalled for manufacturing quality issues

Baxter is recalling 17 intravenous (IV) drug products for manufacturing quality problems, called CGMP deviations, which are lapses in the required production standards. The products include vancomycin, daptomycin, clindamycin, famotidine, dexmedetomidine, vasopressin, pantoprazole, insulin, nicardipine, and amiodarone, plus the brand names Myxredlin, CARDENE IV, and Nexterone. They were distributed nationwide, in Puerto Rico, and in Chile, and no injuries have been reported.

The agency lists each product separately. Check every one you might have.

More from Baxter

See all

Related topics

OtherDrugsSold nationwideMore from FDA Drug